Advertisement
Advertisement

CRIS

CRIS logo

Curis Inc

0.56
USD
Sponsored
-0.02
-2.77%
May 08, 15:57 UTC -4
Closed
exchange

After-Market

0.59

+0.03
+4.99%

Curis Inc Profile

About

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.

Info & Links

CEO

James E. Dentzer

Headquarters

128 SPRING STREET, BUILDING C, SUITE 500
LEXINGTON, MA 02421, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.curis.com

Auditor

PricewaterhouseCoopers LLP

Share holders

99

Employees

24

Curis Inc Statistics

Valuation Measures

Market Capitalization2

23.55M

Enterprise Value

18.49M

Enterprise Value/EBITDA(ttm)

-3.33

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

2.16

Price to Book(mrq)

1.21

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

99.59%

Operating Margin(ttm)

-368.22%

Profit Margin(ttm)

174.72%

Return on Equity(ttm)

--

Return on Invested Capital(ttm)

629.10%

Return on Assets(ttm)

-119.73%

Income Statement

Revenue(ttm)

9.44M

Revenue Per Share(ttm)

0.24

Gross Profit(ttm)

9.40M

EBITDA(ttm)3

-5.54M

Net Income Available to Common(ttm)

-7.58M

Diluted EPS(ttm)

-1.19

Share Statistics

Beta (5Y Monthly)

3.15

52-Week Change

-73.29%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

39.98M

Dividend Yield

0.00%

Float4

37.81M

% Held by Insiders

5.42%

% Held by Institutions

29.97%

Balance Sheet

Total Cash(mrq)

5.06M

Total Cash Per Share(mrq)

0.13

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

0.49%

Quick Ratio(mrq)

0.49%

Book Value Per Share(mrq)

0.42

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.07

Free Cash Flow(ytd)

-27.20M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement